Fig. 6: Bridging efficacy study with LukAB CC8Δ10C and LukAB RARPR-33 showing improved toxin neutralization for LukAB RARPR-33. | npj Vaccines

Fig. 6: Bridging efficacy study with LukAB CC8Δ10C and LukAB RARPR-33 showing improved toxin neutralization for LukAB RARPR-33.

From: A SpA+LukAB vaccine targeting Staphylococcus aureus evasion factors restricts infection in two minipig infection models

Fig. 6

Serum obtained from the study described in Fig. 5 was used in toxin neutralization assays. The fold increase in IC50 toxin neutralization titers between day 0 (three weeks post the third immunization, before challenge) and day -63 (pre-immunization) is shown as the geometric mean for each group against each LukAB variant. The different experimental groups are color coded. Statistically significant differences between LukAB CC8Δ10C and LukAB RARPR-33 are indicated. The differences between LukAB CC8Δ10C and LukAB RARPR-33 compared to the AS01B group are not shown in the Figure but were statistically significant P < 0.05, (except for LukAB CC8Δ10C, CC5 neutralization). Statistical differences were determined using a Tobit model with a Bonferroni post-hoc test to correct for multiple comparisons. TNA, toxin neutralization assay (in vitro). AS01B Adjuvant System AS01B, CC clonal complex, LukAB leukocidin AB, SpA Staphylococcal protein A.

Back to article page